Vasoactive Intestinal Peptide
A 28-amino-acid endogenous neuropeptide that activates VPAC receptors and regulates vascular, pulmonary, gastrointestinal, neural and immune functions.
- Human evidencen/a
- Animal evidencen/a
- Mechanisticn/a
- Safety knowledgen/a
- Editorial confidence5/5
Evidence Snapshot
- Overall
- 3/5Moderate certainty (with caveats)
- Human
- 3/5Multiple human studies
- Animal
- 0/5None identified
- In-vitro
- 0/5None identified
- Safety
- 2/5Partially characterised safety
Scientific identity
- Sequence
- His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn
- Peptide family
- Secretin-glucagon peptide family
- Entity class
- Endogenous neuropeptide
- Alternative names
- Vasoactive intestinal peptideVIPVasoactive intestinal polypeptideAviptadil
Originally isolated from intestine as a potent vasodilatory peptide and subsequently recognised as a widespread neurotransmitter and immunoregulatory peptide.
Proposed Mechanisms
- Immune modulation →supported
- VPAC receptor signalling →strong
- Nitric oxide / blood flow →supported
Reported / Studied Uses
- Anxiety / StressEvidence · low
- Gut Health / Gut BarrierEvidence · low
- Immune Function / InflammationEvidence · weak
- Rheumatoid ArthritisEvidence · needs review
- Libido and sexual functionEvidence · moderate
Human Evidence
Human studies demonstrate vasodilation, headache and migraine provocation, pulmonary effects and activity in combination erectile-dysfunction therapy.
Animal Evidence
Extensive preclinical evidence spans pulmonary, inflammatory, gastrointestinal, reproductive and neurological systems.
Safety & Unknowns
Regulatory Status
| Country | Status | Notes |
|---|
Community Observations
References
- No verified references linked yet. Editors will add primary sources.
Full Disclaimer
This page is for educational information only. It does not constitute medical advice, diagnosis, treatment, dosing guidance, or a recommendation to use any peptide, medicine or research chemical. Many peptides discussed on Atlas are not approved for human use in most jurisdictions and may have limited or unknown long-term safety data.
Community observations shown on this page are anonymised, moderated and observational only. They do not establish safety or effectiveness.
Always consult a qualified healthcare professional before making decisions about your health. See medical disclaimer and methodology.
Explore further
from the knowledge graph- Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial2021 · randomized_clinical_trial
- VPAC and PAC receptors: from ligands to function2009 · receptor_pharmacology_review
- Inhalation of vasoactive intestinal peptide in pulmonary hypertension2008 · acute_human_inhalation_study